Beigene has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company is offering 5.5 million American depositary shares (ADSs) in the expected price range of $22 to $24 per ADS, with an overallotment option for an additional 825,000 ADSs. Each ADS is valued at approximately 13 ordinary shares. The company intends to list on the Nasdaq under the symbol BGNE.
The underwriters for the offering are Goldman Sachs, Morgan Stanley, Cowen and Baird.
This globally focused biopharmaceutical company is dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. It believes the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival. Beigene further believes that discovery of next-generation cancer therapies requires new research tools.
The company’s strategy is to advance a pipeline of drug candidates with the potential to be best-in-class monotherapies and also important components of multiple-agent combination regimens. Over the past five years, using its cancer biology platform, Beigene has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton’s tyrosine kinase (BTK), RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.
At the end of November, Beigene’s four clinical-stage drug candidates have been dosed in a total of 265 patients. It has Investigational New Drug Applications in effect for BTK and PD-1 inhibitors with the U.S. Food and Drug Administration (FDA), and has received approval of its Clinical Trial Application for its RAF dimer inhibitor from the China Food and Drug Administration (CFDA).
The company intends to use the net proceeds from this offering to further develop its pipeline. Also it may use a portion of the net proceeds for the acquisition or licensing, as the case may be, of additional technologies, other assets or businesses, or for other strategic investments or opportunities. The remainder will be used for working capital and general corporate purposes.